Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.64 |
| ▸ | KIF11 | P52732 | 4/20 | 0.57 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.56 |
| ▸ | P2RX3 | P56373 | 13/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5435578 | 0.88 | DRD2 (0.58) | DRD2TBXA2RKIF11DCTPP1P2RX3 | |
| SCHEMBL5364560 | 0.84 | DRD2 (0.58) | DRD2TBXA2RKIF11P2RX3 | |
| SCHEMBL5440812 | 0.82 | P2RX3 (0.55) | DRD2TBXA2RKIF11P2RX3 | |
| SCHEMBL5361429 | 0.80 | DRD2 (0.53) | DRD2TBXA2RKIF11P2RX3 | |
| SCHEMBL5439917 | 0.80 | DRD2 (0.67) | DRD2TBXA2RKIF11P2RX3CYP2C9 | |
| SCHEMBL10047980 | 0.79 | DRD2 (0.68) | DRD2TBXA2RKIF11P2RX3 | |
| SCHEMBL13982891 | 0.77 | KIF11 (0.65) | DRD2TBXA2RKIF11P2RX3CYP2C9 | |
| SCHEMBL10055370 | 0.76 | P2RX3 (0.69) | P2RX3 | |
| SCHEMBL13983222 | 0.75 | KIF11 (0.69) | DRD2TBXA2RKIF11P2RX3CYP2C9 | |
| SCHEMBL9198925 | 0.74 | AGTR1 (0.78) | DRD2TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7301036-B2 | Cyclic guanidines, compositions containing such compounds and methods of use | MERCK & CO., INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070105930-A1 | Cyclic guanidines, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105930-A1 | Cyclic guanidines, compositions containing such compounds and methods of use | GCGR, GLP1R, GCG | DRD2 1040/4885TBXA2R 35/4885KIF11 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.